This is an open access article distributed under the terms of the Creative Commons Attribution License (
Computational and experimental evidence is given for alternative splicing at the unusual GYNGYN motif in several species, enabling in most cases subtle protein variations.
Splice donor sites have a highly conserved GT or GC dinucleotide and an extended intronic consensus sequence GTRAGT that reflects the sequence complementarity to the U1 snRNA. Here, we focus on unusual donor sites with the motif GYNGYN (Y stands for C or T; N stands for A, C, G, or T).
While only one GY functions as a splice donor for the majority of these splice sites in human, we provide computational and experimental evidence that 110 (1.3%) allow alternative splicing at both GY donors. The resulting splice forms differ in only three nucleotides, which results mostly in the insertion/deletion of one amino acid. However, we also report the insertion of a stop codon in four cases. Investigating what distinguishes alternatively from not alternatively spliced GYNGYN donors, we found differences in the binding to U1 snRNA, a strong correlation between U1 snRNA binding strength and the preferred donor, over-represented sequence motifs in the adjacent introns, and a higher conservation of the exonic and intronic flanks between human and mouse. Extending our genome-wide analysis to seven other eukaryotic species, we found alternatively spliced GYNGYN donors in all species from mouse to
In contrast to alternative splicing in general, GYNGYN donors in addition to NAGNAG acceptors enable subtle protein variations.
Given the rather limited number of human genes [
The skipping of an exon is the most frequent alternative splice event, followed by alternative splice donor and acceptor sites [
The recognition of donor and acceptor splice sites is different. While the acceptor AG and its preceding polypyrimidine tract is recognized by the U2AF heterodimer [
Here we investigate whether alternative splicing at a GT or GC donor dinucleotide 3nt up- or downstream is possible. This type of alternative splicing requires a GYNGYN donor motif (Y stands for C or T) and is of interest because it would result in similar subtle protein changes like at NAGNAG tandem acceptors and thus increase the proteome plasticity. We found expressed sequence tag (EST) and/or mRNA evidence for alternative splicing at 110 human GYNGYN tandem donors and confirm the existence of both splice forms by RT-PCR experiments in seven cases. We report the occurrence of alternative splicing at GYNGYN tandem donors in six other animals and a plant. Analyzing the GYNGYN motifs that do and do not allow alternative splicing, we found significant differences in the stability of the U1 snRNA binding, conserved exonic and intronic flanks between human and mouse, and over-represented sequence motifs in the intronic flanks.
Although the great majority of introns begins with a GT dinucleotide, a small fraction of 0.76% begins with GC [
By searching dbEST and the human mRNAs from GenBank, we identified experimental evidence for alternative splicing at 110 (1.3% of 8,550) tandem donors (in the following we term these tandem donors 'confirmed') (Table
A or G is strongly preferred at intron position +3 for standard donor sites GTN, while T and C have lower frequencies [
Furthermore, we generated a sequence logo for the genomic context of confirmed tandems, unconfirmed GYNGYNs where either the e or i donor is confirmed, and donor sites without a GYNGYN motif (Figure
In some cases it has been reported that single nucleotide polymorphisms (SNPs) in the vicinity of donor sites lead to a shift in the splice site [
To further support the EST-derived confirmation of alternative splice events at tandem donor sites, we performed RT-PCR in several human tissues. We selected eight genes with confirmed GYNGYNs having at least three ESTs for e and i transcripts (Table
The U1 snRNA determines the donor site by base pairing with the mRNA [
Nevertheless, there are 17 of the 81 confirmed GTNGTN tandems with more ESTs for the i donor than the e donor. Therefore, we compared the free energy values and found that 15 of these 17 cases (88%) have a lower free energy for the i donor, thus allowing a more stable U1 binding (Figure
Since only a small fraction of all human tandem donors are confirmed, we searched for differences between confirmed and unconfirmed ones. Plotting the free energy values for e and i donors shows that most confirmed GTNGTNs are located at the left part (Figure
We assumed that the strength of both donors might be a criterion to distinguish functional from non-functional tandem donors. To test this experimentally, we selected nine unconfirmed GTNGTNs with a low free energy for both donor sites for experimental verification. As for confirmed GTNGTNs, RT-PCR products were directly sequenced and the sequencing traces were inspected for overlapping sequences. For none of the nine candidates, we found evidence for alternative splicing at the tandem donor, suggesting that the majority of unconfirmed GTNGTNs is presumably not alternatively spliced. However, our direct sequencing approach does not exclude that the alternative transcript is expressed at a low frequency.
We conclude that: stable U1 binding is necessary but not sufficient for alternative tandem donor splicing; the currently confirmed GYNGYN represent a large fraction of all functional tandem donors; and, in contrast to NAGNAG acceptors [
Since the free energy of U1 binding seems not to be the only discriminative criterion, we searched for other differences between confirmed and unconfirmed GTNGTNs. The regulation of alternative splicing often involves auxiliary exonic and intronic splice enhancer and silencer elements (abbreviated ESE, ESS, ISE, and ISS, respectively) that are bound by trans-acting RNA-binding proteins like serine/arginine rich (SR) proteins and hnRNPs [
To find out if specific ISE hexamers are statistically over-represented, we used a resampling strategy. We randomly sampled 10,000 sets, each comprising 81 intron flanks from unconfirmed GTNGTNs. We estimated the P-value as the fraction of random sets with a higher frequency of a given ISE hexamer compared to the observed frequency in confirmed tandem donors. CGGGGT is the only one among the 133ISE motifs that is significantly over-represented in the vicinity of confirmed GTNGTN donors as all 10,000 random sets have a lower frequency (P < 1/10,000 × 133 = 0.0133 to correct for multiple testing). To find out if other sequence motifs are over-represented in the intron flanks of confirmed tandem donors, we repeated this procedure with tetramers. A word length of 4 nucleotides was chosen to account for the rather small data set. We only compared the 119 tetramers that occur at least with the expected frequency in the intron flanks of confirmed GTNGTNs. We found a significant overrepresentation for GGGT and CGGG (both have a higher frequency in only two random sets, P < 3/10,000 × 119 = 0.0357), while the tetramer GGGG has a corrected P-value slightly above the 0.05 threshold (higher frequency in five random sets, P < 0.0714). Since both GGGT and CGGG are substrings of the over-represented ISE CGGGGT, no new sequence motifs were found. The common feature of the over-represented sequence motifs is the G triplet. Interestingly, this motif occurs in 82 of the 133 ISEs [
Of the 81 confirmed GTNGTNs, 72 (89%) are located downstream of a coding exon; thus, alternative splicing at these sites results in 3 nucleotide indels into the coding sequence. The effect for the protein depends on the phase of the intron as well as the sequence of the GTNGTN and the upstream/downstream exon. In intron phase 0 (intron location between two codons) the GTN of the i donor is inserted/deleted and codes for a valine. In intron phase 1 and 2 (location between the first and second codon position, respectively), three different events are possible: indel of a single amino acid; exchange of a dipeptide and a different amino acid; and indel of a stop codon. Of the 72 GTNGTNs, 37 (51%) are located in phase 0, thus a valine indel is the most frequent event at the protein level. Of the 28 (39%) GTNGTNs in phase 1, 18 result in single amino acid events (14 times glycine, 2 times arginine, 2 times serine), 8 exchange a dipeptide and an unrelated amino acid and in two cases splicing at the i donor creates a stop codon. The 7 (10%) confirmed GTNGTNs in phase 2 are interesting since they either result in indels of rare amino acids (three times tryptophan, one cysteine, one tyrosine) or insert/delete a stop codon in two cases.
Thus, alternative splicing at four tandem donors has a more drastic impact on the proteins by the indel of a stop codon (phase 1:
The protein impact of the 28 GTNGCN and GCNGTN tandems that are located within the CDS comprise 22 single amino acid indels (intron phase 0: alanine, valine; phase 1: arginine, glycine, serine; phase 2: arginine, glutamine, leucine) and 6 dipeptide exchanges (all in phase 1). Compared to the protein events for GTNGTNs, the indel of alanine, glutamine and leucine is only observed for tandems with a GC donor.
Next, we compared the frequency of single amino acid events in phase 1 and 2 for confirmed and as a control for unconfirmed GTNGTNs. While only 42% (495 of 1,180) unconfirmed tandem donors in phase 1 result in a single residue indel, this percentage is significantly higher for confirmed tandems (64%, 18 of 28, Fisher's exact test: P = 0.02). The small number of phase 2 tandems does not allow a significant result, although the same trend is visible (100%, 5 of 5 confirmed tandems; 76%, 431 of 566 unconfirmed tandems; leaving stop codon events out). These findings argue for a preference to insert/delete only single amino acids, presumably because this is a less dramatic event compared to dipeptide exchanges. However, we cannot exclude the possibility that this result is an indirect consequence of a sequence bias of the GTNGTN motif and its context for confirmed tandems that primarily aims at a more stable U1 snRNA binding. For GTNGCN and GCNGTN tandems, only phase 2 donors result in a high percentage of single amino acid indels (100%, 5 of 5 confirmed; 81%, 781 of 962 unconfirmed) while phase 1 events show no bias (40%, 4 of 10 confirmed; 48%, 524 of 1103 unconfirmed).
Further, we asked whether alternative splicing at GYNGYN donors is limited to humans or a general phenomenon. Therefore, we extended our analysis to the RefSeq transcripts of mouse (
As in humans, the preferred motif for confirmed GTNGTNs is GTRGTR in all species except for
Having observed several alternative GTNGTN splice events in human and mouse, we found conservation of the GTNGTN motif for 53 (65.4%) of the 81 human confirmed GTNGTNs. To assess whether this percentage is high or not, we counted GTNGTN conservation for the 3,909 unconfirmed tandems (162 of the 4,071 have no orthologous locus in mouse) and found a very similar percentage of 65.5% (2,561 of 3,909). The fraction of tandem donors that have a completely identical GTNGTN pattern in mouse is also equal: 40 of 81 (49.4%) confirmed, 1,939 of 3,909 (49.6%) unconfirmed. Thus, there is no evidence for a general selection pressure to maintain confirmed tandem donors since the divergence of the human-mouse ancestor.
However, a considerable fraction (10 of 53 (19%)) of the conserved and confirmed human GTNGTNs is also confirmed in mouse. For example, the GTAGTT donor of intron 21 of
The intronic flanks of alternative exons are significantly more conserved in mouse compared to the flanks of constitutive exons, a fact which is presumably attributed to the force to maintain regulatory elements [
We report the occurrence of alternative splice donor usage for GTNGTN, GTNGCN, and GCNGTN motifs in eight investigated eukaryotic species. Apart from our experimental verification of seven human and one mouse GYNGYN donors, several lines of evidence indicate that the majority of observed events is attributable to real alternative splicing. Firstly, numerous GTNGTNs are confirmed by multiple ESTs/mRNAs and for several of these events both e and i transcripts are deposited in the RefSeq database. Secondly, the existence of orthologous tandem donors that are confirmed in two or more species makes EST artifacts or database errors unlikely. Thirdly, these GTNGTN donors have a higher conservation of the exonic and intronic flanking regions, a situation that is typical for conserved alternative splice events [
We found that the percentage of donor sites with a GYNGYN motif as well as the percentage of tandem donors that are confirmed is very similar between the eight investigated species (tolerating some variation probably due to differences in the number of ESTs and mRNAs). Given the large evolutionary distance between
Although only a fraction of the tandem donors is confirmed, we found features that distinguish confirmed from unconfirmed ones. Since the non-annotated donor of unconfirmed tandems does not allow a sufficiently stable binding to the U1 snRNA, the other donor is used exclusively in the splice process. For confirmed tandem donors, both sites allow a stable binding to U1 snRNA. However, in most of the confirmed cases one donor has a better strength and this results in its preferred usage as measured by the EST ratio between both transcripts. The second discriminative feature is the overabundance of G triplets in the intronic flanks of confirmed GTNGTNs, especially for introns shorter than 200 nt. This triplet is the core of many known ISE motifs [
Most confirmed GYNGYNs have a low free energy of U1 snRNA binding to both the e and i donor, suggesting that the U1 snRNA can stably bind to both sites. However, there are a few exceptions where one donor is much stronger than the other one in a confirmed tandem (Figure
Previously, we found that the impact of SNPs in NAGNAG acceptors on alternative splicing can be accurately predicted [
Higher eukaryotes typically express multiple transcripts and proteins from a single gene. A prominent mechanism is alternative splicing as about 74% of the human multi-exon genes express more than one splice variant [
Despite many GYNGYN donors, we found only a minority that allows alternative splicing. Nevertheless, among the human confirmed and evolutionary conserved tandem donors we found a significant fraction to be confirmed in other species. Moreover, the splicing pattern of the
We downloaded from the UCSC Genome Browser [
For checking if a GYNGYN donor is confirmed (at least one EST/mRNA for the e as well as i transcript), we compiled two search strings: 30 nucleotides from the upstream exon and 30 nucleotides from the downstream exon for the i transcript; and 30 nucleotides from the upstream exon, the GYN of the i donor and 30 nucleotides from the downstream exon for the e transcript. Then, we used BLAST against all ESTs and mRNAs for the respective species, allowing at most one mismatch or one gap but demanding exact identity for the region 27-33 for i-transcripts and 27-36 for e-transcripts. The ESTs were downloaded from the UCSC Genome Browser (est.fa.gz, November 2005). mRNAs were downloaded from GenBank at the same date as the ESTs. For acceptor sites with a NAGNAG pattern, we repeated the analysis using analogous procedures and the same data described above.
Human-mouse genomic alignments (hg17-mm6) were downloaded from the UCSC Genome Browser (vsMm6/axtNet, March 2005). We used the genomic position of human and mouse donor sites to select the respective alignment chain. From the alignments, we determined whether a human GTNGTN donor is conserved (there is also a GTNGTN motif in mouse) or completely identical. For the per-position identity computation, we considered the alignment part up to 100 positions upstream and downstream. For each position, we counted how often there is identity between human and mouse (Nid), and how often there is a mismatch or gap (Nmm). The per-position identity value is Nid/(Nid+Nmm). Alignment positions with an 'N' aligned to a nucleotide were ignored.
To find tandem donors that are orthologous and confirmed in human and mouse, we used BLAST with the human-confirmed search strings against the search strings of the mouse-confirmed GTNGTNs. Furthermore, we used BLAST with the human-confirmed search strings against the mouse ESTs and mRNAs. Using the UCSC and Ensembl genome browser, we manually checked each hit with an E-value of less than 1e-3 for being alternatively spliced in both species and for having a true orthologous relationship.
We extracted a 9 nucleotide genomic context (3 nucleotides upstream to 3 nucleotides downstream of the GYN) for the e and i donor of confirmed and unconfirmed GYNGYNs. The free energy and number of base pairs with the U1 snRNA were computed according to [
We extracted the genomic sequence 100 nucleotides upstream (exonic) and 100 nucleotides downstream (intronic) of GTNGTN donor motifs. To identify over-represented ISE hexamer motifs, we used a resampling procedure to estimate the P-value for a higher frequency in the intronic flanks of confirmed GTNGTNs. To this end we randomly sampled 10,000 sets of 81 intronic flanks of unconfirmed GTNGTNs and computed the frequency for each of the 133 ISE motifs in the 10,000 random sets. The P-value for one ISE is the fraction of random sets with a higher frequency compared to the observed frequency for confirmed GTNGTNs. To correct for multiple testing, each P-value is multiplied by 133. For the general search for over-represented motifs, we decided to use tetramers (word length 4 nt) instead of hexamers since the dataset of the confirmed tandems is rather small. Since we were searching for over-represented motifs in the intronic flanks of confirmed GTNGTNs, we expected that such motifs occur at least with the expected frequency under a null model and with a significant higher frequency compared to the flanks of unconfirmed GTNGTNs. There are 97 overlapping tetramers in a 100 nucleotide sequence, thus we analyzed a total of 81 × 97 = 7,857 tetramer occurrences. For complete random sequences, each tetramer should occur 7857/256 = 30.7 times. Since intron sequences are not random, we found a total of 119 tetramers that occur 30 times or more in the flanks of confirmed GTNGTNs. For these 119 tetramers, we repeated the procedure described above but multiplied the P-value by 119.
Eight genes with multiple EST evidence for alternative splicing at a tandem donor were analyzed by RT-PCR in different tissues by using cDNA from multiple tissue cDNA panels (BD Clontech Germany, Heidelberg, Germany) as PCR templates. Primers were designed for the exons flanking the tandem donor with distances to these donors that allow reliable amplification and sequencing. PCR was performed in a total volume of 25 μl using ReadyToGo PCR beads (GE Healthcare Europe, Munich, Germany) with 5 pmoles of each primer and 1 μl of cDNA. Cycling conditions were 94°C for 30 s followed by 35 cycles with 94°C for 20 s, 57°C for 30 s and 72°C for 30 s, followed by a final extension at 72°C for 10 minutes. Amplified fragments were precipitated with ethanol and ammonium acetate, washed with ethanol and sequenced using DyeTerminator chemistry (Applied Biosystems, Foster city, USA) and the respective PCR primers on a 3730 xl DNA Analyzer (Applied Biosystems). Genes and their primer sequences were:
The same strategy was applied to a set of genes with unconfirmed tandem splice donors. Genes and their primers were:
To facilitate further experimental and computational studies of tandem splice
sites, we recently developed a database, TassDB [
The following additional data are available with the online version of this paper. Additional data file
Data for all human confirmed GYNGYN splice donor sites identified in this study
Click here for file
Data on the strength of e and i human GYNGYN donors
Click here for file
Confirmed GYNGYN donors for seven species
Click here for file
Selected sequence traces that exemplify the experimental verification of GYNGYN donors
Click here for file
Control experiments for detecting minor splice forms by direct sequencing of RT-PCR products
Click here for file
We thank Gene Yeo for providing the ISE hexamer list and Anke Busch for critical reading of the manuscript. The skillful technical assistance of Beate Szafranski and Ivonne Görlich is gratefully acknowledged. This work was supported by grants from the German Ministry of Education and Research to SS (01GS0426) and to MP (01GR0504, 0313652D) as well as from the Deutsche Forschungsgemeinschaft (SFB604-02) to MP.
Nomenclature for tandem donor sites and transcripts.
Sequence logos of the 12 nucleotide donor context (3 nucleotides upstream to 6 nucleotides downstream of the GYN).
Alternative splicing at the tandem donor of exon 21 of
The free energy values in kcal/mol for e and i donor of human
Per position identity values in human mouse alignments for the region 30 nucleotides up- and downstream of the GTNGTN motif. The black line represents unconfirmed human GTNGTN donors, the blue line confirmed human tandem donors with a conserved GTNGTN motif in mouse, and the green line conserved GTNGTNs that are confirmed in human and mouse. To avoid large variations due to the low case numbers, we calculated for each position the average of this and the three positions up- and downstream.
Human tandem donor sites divided into the four different GYNGYN patterns
| Splice donor pattern | Number and % of tandem donors* | Number and % of confirmed donors | ||
| GTNGTN | 4,152 | 2.51% | 81 | 1.95% |
| GTNGCN | 856 | 0.52% | 14 | 1.64% |
| GCNGTN | 3,510 | 2.12% | 15 | 0.43% |
| GCNGCN | 32 | 0.02% | 0 | 0.00% |
| GYNGYN | 8,550 | 5.17% | 110 | 1.29% |
*Percent of all 165,295 annotated donor sites
Experimental verification of human GYNGYN donors
| Gene symbol | RefSeq ID | Upstream exon | Annotated donor | Pattern | Transcripts found* |
|
|
NM_013367 | 18 | i | GTAGTA | e < i |
|
|
NM_001146 | 4 | e | GTGGTA | e > i |
|
|
NM_001031702† | 16 | e | GTGGTG | e > i |
|
|
NM_005676† | 10 | e | GTGGTG | e < i |
|
|
NM_005488 | 14 | i | GTAGTA | e < i |
|
|
NM_003150† | 21 | i | GTAGTT | e > i |
|
|
NM_138362 | 2 | e | GTAGCA | e < i |
|
|
NM_206943 | 14 | e | GTAGCC | e |
*e < i means higher expression of i transcripts; e > i means higher expression of e transcripts; e means only e transcripts found. All sequence traces are deposited in the NCBI Trace Archive (Additional data file 4). †The alternative donor is annotated in another RefSeq transcript.
Characteristics of U1 snRNA binding to human confirmed and unconfirmed GYNGYN donors
| Average | ||||||
|
|
||||||
| Free energy (kcal/mol)* | Number of base pairs* | Maximum entropy score† | ||||
| i | e | i | e | i | e | |
| Unconfirmed, e annotated | -1.92 | -5.46 | 3.12 | 6.69 | -18.13 | 7.95 |
| Unconfirmed, i annotated | -5.01 | -0.24 | 6.49 | 3.30 | 4.63 | -16.02 |
| Confirmed | -3.68 | -4.25 | 4.84 | 6.09 | -5.88 | 1.65 |
*Computed with the Splice-site Analyzer tool [67]. †Computed with MaxEntScan [68].
GTNGTN, GTNGCN and GCNGTN donors in eight investigated species
| Species | Number of donors* | GTNGTN | GTNGCN and GCNGTN | ||||||
|
|
|||||||||
| Observed | Confirmed | Observed | Confirmed | ||||||
|
|
165,295 | 4,152 | 2.51%† | 81 | 1.95%‡ | 4,398 | 2.66%§ | 29 | 0.66%¶ |
|
|
125,332 | 3,188 | 2.54% | 49 | 1.54% | 3,237 | 2.58% | 12 | 0.37% |
|
|
53,631 | 1,424 | 2.66% | 12 | 0.84% | 1,440 | 2.69% | 3 | 0.21% |
|
|
19,793 | 554 | 2.80% | 1 | 0.18% | 553 | 2.79% | 2 | 0.36% |
|
|
29,091 | 619 | 2.13% | 5 | 0.81% | 699 | 2.40% | 1 | 0.14% |
|
|
40,811 | 1,274 | 3.12% | 19 | 1.49% | 1,906 | 4.67% | 5 | 0.26% |
|
|
92,938 | 3,195 | 3.44% | 26 | 0.81% | 2,838 | 3.05% | 1 | 0.04% |
|
|
112,684 | 3,541 | 3.14% | 36 | 1.02% | 2,091 | 1.86% | 8 | 0.38% |
*Total number of all unique donor sites annotated in RefSeq transcripts; for
Number of confirmed GTNGTN donors divided into three groups according to their motif
| GTRGTR | GTRGTT + GTTGTR + GTTGTT | GTCGTN + GTNGTC | ||||
|
|
70 | 86% | 8 | 10% | 3 | 4% |
|
|
44 | 90% | 4 | 8% | 1 | 2% |
|
|
10 | 83% | 2 | 17% | 0 | 0% |
|
|
0 | 0% | 1* | 100% | 0 | 0% |
|
|
5* | 100% | 0 | 0% | 0 | 0% |
|
|
14 | 74% | 5 | 26% | 0 | 0% |
|
|
11 | 42% | 15 | 58% | 0 | 0% |
|
|
16 | 44.5% | 16 | 44.5% | 4 | 11% |
*Case number too low to draw any conclusion.
NAGNAG acceptors for seven species
| Species | Number of acceptors* | NAGNAG acceptor | HAGHAG acceptor | Confirmed NAGNAG acceptor | Confirmed HAGHAG acceptor | ||||
|
|
164,841 | 9,465 | 5.7%† | 3,530 | 37.3%‡ | 1,511 | 16%§ | 1,373 | 90.9%¶ |
|
|
125,233 | 7,116 | 5.7% | 2,662 | 37.4% | 1,087 | 15.3% | 1,022 | 94.0% |
|
|
53,598 | 3,080 | 5.7% | 1,098 | 35.6% | 215 | 7.0% | 202 | 94.0% |
|
|
19,794 | 1,069 | 5.4% | 401 | 37.5% | 97 | 9.1% | 92 | 94.8% |
|
|
29,067 | 1,540 | 5.3% | 484 | 31.4% | 132 | 8.6% | 118 | 89.4% |
|
|
39,441 | 1,584 | 4.0% | 859 | 54.2% | 177 | 11.2% | 170 | 96.0% |
|
|
92,867 | 4,184 | 4.5% | 2,637 | 63.0% | 33 | 0.8% | 33 | 100.0% |
H stands for A, C, or T. *Total number of all unique acceptor sites annotated in RefSeq transcripts. †Number of NAGNAG acceptors/number of all acceptors. ‡Number of HAGHAG acceptors/number of NAGNAG acceptors. §number of confirmed NAGNAG acceptors/number of NAGNAG acceptors. ¶Number of confirmed HAGHAG acceptors/number of confirmed NAGNAG acceptors.